REPLICEL LIFE SCIENCE ORD - REPCF STOCK NEWS

RepliCel Life Sciences announced the trademark registration of its DermaPrecise Injector, a product designed for precise dermal injections, enhancing potential applications in both medicine and aesthetics.

CEO R. Lee Buckler highlighted its value in delivering cell and gene therapies as well as various aesthetic treatments. The device promises controlled injection depth, reduced pain, and efficient delivery. RepliCel is preparing to submit data to regulatory agencies for market approval, targeting key regions including the U.S., Europe, Hong Kong, and Japan.

RepliCel Life Sciences has announced progress in its dermal injector program, with testing moving to the next phase. Recent results confirmed that the injector meets primary specifications, though some technical issues were identified and addressed. The company plans to submit its marketing application soon, despite a slight delay due to necessary modifications. The injector features advanced electronic control and is aimed at various applications, including aesthetic procedures. RepliCel continues to engage strategic partners for further development and clinical testing.

RepliCel Life Sciences has initiated an arbitration claim against Shiseido following unsuccessful attempts to resolve a dispute regarding a license for cell therapy technology aimed at treating androgenetic alopecia. The arbitration, governed by ICDR rules, seeks either compliance with the original agreement or the return of the license and associated data. RepliCel alleges Shiseido breached the terms, potentially resulting in re-licensing opportunities in Asia. The company focuses on developing regenerative therapies for aesthetic and orthopedic conditions.

RepliCel Life Sciences Inc. (REPCF) has appointed Kunihiko Suzuki as Senior Strategic Advisor to its Board of Directors, focusing on expanding the company's operations in Japan. Suzuki, a prominent figure in Japan's regenerative medicine sector, aims to enhance RepliCel's therapeutic product pipeline. The company is gearing up for advanced clinical studies of its regenerative therapies, RCS-01 and RCT-01, under Japan's regulatory framework for regenerative medicine. RepliCel seeks to establish itself as a leader in this market, leveraging Suzuki's expertise and network.

RepliCel Life Sciences announces significant progress in its collaboration with the University of Victoria. The first-stage project led to a Technology Evaluation and License Option agreement for a US patent on microcarriers in cell therapy. The second phase has received three years of funding from the Mitacs Accelerate program, focusing on optimizing manufacturing for RepliCel's cell therapy products. The project aims to enhance commercial-scale production and advance innovations in therapeutic cell culture.

RepliCel Life Sciences Inc. (OTC PINK:REPCF) has submitted a manufacturing approval application to Japan's Ministry of Health for its RCT-01 and RCS-01 cell therapies. Following successful Phase 1 studies, these therapies target chronic tendinopathy and aging skin, respectively. The company aims to initiate clinical research under Japan's Act for Safety of Regenerative Medicine, with commercial launch potential upon meeting regulatory endpoints. Industry collaboration includes advisors and clinical research organizations to ensure successful product development.

RepliCel Life Sciences (OTCQB:REPCF) has appointed Gary Boddington to its board, enhancing its governance and oversight. Boddington, a seasoned CEO with experience in global business development, brings expertise in digital transformation and capital raising. The company has also granted 1,715,000 stock options to directors and consultants at a price of $0.40 per share, vesting over two years. RepliCel focuses on regenerative medicine for aesthetic and orthopedic conditions, with cell therapies actively developed in collaboration with partners in the U.S. and China.

RepliCel Life Sciences has received the initial units of its dermal injector and is nearing the completion of preliminary functional testing. This phase is essential for launching larger-scale production and regulatory submissions aimed at marketing approval in the U.S. and Japan. A comprehensive testing program is in place for over 40 units to ensure regulatory compliance. RepliCel is also collaborating with MainPointe Pharmaceuticals for U.S. commercialization and planning for a clinical study in Japan.

RepliCel Life Sciences has engaged Accerise Inc. to facilitate clinical studies for its cell therapy products in Japan. The studies will evaluate RCS-01 for skin rejuvenation and RCT-01 for tendon regeneration, building on previous phase 1 trials in Germany and Canada. Following compliance with Japan's Act for Safety of Regenerative Medicine, successful outcomes may lead to product commercialization. Accerise will help design study protocols and ensure adherence to GCP standards, aiming for high-quality data during this critical phase.